Dr. Dustin T. Smith and Dr. Joanna M. Bonsall reviewed nine key updates in hospital medicine at SHM Converge 2025.

Frailty is often a concern when introducing novel therapies in HF patients, as it is typically linked with poorer outcomes ...

Learn how finerenone improves heart failure outcomes in frail patients - discover the latest evidence and clinical guidance.

The FINEARTS-HF Trial. In FINEARTS-HF, 6016 patients with heart failure and a left ventricular ejection fraction of at least 40% (mean, 54%) were randomized to finerenone (at a maximum dose of 20 ...

Regardless of chronic obstructive pulmonary disease status, finerenone mitigates clinical events and symptoms in patients with HFmrEF or HFpEF.

CHICAGO — Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or heart failure with mildly reduced or preserved ejection ...

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA), is the first MRA to reach a primary cardiovascular end point in a phase 3 study in this patient population, which ...

The benefit-risk profile of finerenone (Kerendia) for heart failure and mildly reduced or preserved ejection fraction (HFmrEF, HFpEF) was arguably unchanged with delayed initiation, according to ...

Finerenone also reduced urine albumin-creatinine ratio (UACR) by 30% (95% CI 25-34) over 6 months compared with placebo, which was largely maintained throughout the 36-month follow-up.

Finerenone reduced the risk of the primary composite outcome more effectively in patients enrolled within 7 days (RR, 0.74; 95% CI, 0.57-0.95) and between 7 days and 3 months ...

Finerenone, a nonsteroidal MRA, was among the drugs in the trials. If the FDA expands the use of finerenone as a heart failure therapy, cardiologist Dr. Michelle Bloom said, ...

Finerenone, sold under the brand names Kerendia and Firialta, was approved in 2021 by the US Food and Drug Administration to reduce the risk of serious complications in certain adults with chronic ...